<DOC>
	<DOCNO>NCT03059797</DOCNO>
	<brief_summary>To compare effect safety Anlotinib placebo patient small cell lung cancer ( SCLC ) .</brief_summary>
	<brief_title>Study Anlotinib Patients With Small Cell Lung Cancer ( ALTER1202 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<criteria>Histological documentation small cell lung cancer Advanced small cell lung cancer least two chemotherapy regimen , least one measurable lesion ( RECIST1.1 ) 1875 year , ECOG PS:02 , Life expectancy 3 month Main organ function normal Women childbearing potential agree use utilize adequate method contraception ( intrauterine device，contraceptive condom ) throughout treatment least 6 month study stopped；the result serum urine pregnancy test negative within 7 day prior study enrollment，and patient require nonlactating；Man participant agree use utilize adequate method contraception throughout treatment least 6 month study stop Patients participate study voluntarily sign informed consent Patients use anlotinib Patients use target drug ( sunitinib , bevacizumab , endostar ) , Immune target drug 4 week less last cytotoxic therapy , radiation therapy surgery Patients whose primary lesion active bleeding within 4 month Carcinomatous meningitis Patients known central nervous system Patients factor could affect oral medication ( dysphagia，chronic diarrhea , intestinal obstruction etc . ) Patients severe and/or unable control diseases，including： 1 . Blood pressure unable control ideally ( systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg ) ; 2 . Patients Grade 1 high myocardial ischemia , myocardial infarction malignant arrhythmia ( include QTc≥450ms ( male ) , QTc≥470ms（female） ) patient Grade 1 high congestive heart failure ( NYHA Classification ) ; 3 . Patients active unable control serious infection ; 4 . Patients cirrhosis , decompensated liver disease , active hepatitis ; 5 . Patients poorly control diabetes ( fast blood glucose ( FBG ) ＞10mmol/L ) 6 . Urine protein ≥ ++，and 24hour urinary protein excretion＞1.0 g confirm ; Patients nonhealing wound fracture Patients arterial venous thromboembolic event occur within 6 month , cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism Patients drug abuse history unable get rid Patients mental disorder Imaging show tumor involve important blood vessel investigator determine likely followup study cause fatal hemorrhage History immunodeficiency Patients concomitant disease could seriously endanger safety could affect completion study accord investigator ' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>